The studies of the two-antibody cocktail REGN-COV2 include a Phase III trial to prevent infection among people who have been exposed to infected patients and two Phase II/III trials, in hospitalized and non-hospitalized patients with the disease.

LEAVE A REPLY

Please enter your comment!
Please enter your name here